#United States #Tetrous #EnFix #Sherman Oaks #Alpha Medical

Tetrous, Inc. Expands into New Zealand Through Strategic Partnership

Tetrous, Inc., a startup based in Sherman Oaks, California, is making significant strides in the Asia-Pacific market. The company, known for its focus on bone-to-tendon healing techniques post-orthopedic surgery, recently announced a new distribution agreement with Alpha Medical, a prominent distributor situated in New Zealand. This collaboration not only reinforces Tetrous' commitment to enhancing patient recovery but also marks a pivotal movement in their global expansion initiative.

As part of this agreement, Alpha Medical will hold exclusive distribution rights in New Zealand for Tetrous’ innovative EnFix® demineralized bone fiber implants, designed explicitly for enthesis repair. This includes procedures for various joints, such as the shoulder, elbow, hip, knee, and ankle. Alpha Medical has built a reputable name within the industry by providing top-of-the-line, innovative medical products, and their collaboration with Tetrous promises to elevate surgical outcomes and patient recovery experiences.

The Chief Commercial Officer of Tetrous, John Bojanowski, expressed enthusiasm about this partnership, stating, “We are thrilled to partner with Alpha Medical, a respected medical distribution leader in New Zealand. Their expertise with biologic products and commitment to improving patient outcomes makes them the perfect ally to promote and distribute our offerings.” This move is expected to significantly boost the availability of Tetrous products, which have already been commercialized in the United States and Australia through Australian Biotechnologies.

In a further enhancement of their team, Tetrous has welcomed Dr. Craig Ball—a highly regarded shoulder surgeon from New Zealand—into their Clinical Advisory Board. Dr. Ball is keen to integrate Tetrous’ EnFix solutions into his practice at Southern Cross Healthcare, located in Auckland. He has commented on the essential role of biologic augmentation in the healing process of the rotator cuff, noting, “Biologic augmentation in the rotator cuff has not been an easy task to accomplish and yet could be the key to proper healing.” His firsthand experience with the EnFix implants aims to gauge their efficacy as a minimally disruptive option to gynecology treatments.

Brandon Hiini, CEO of Alpha Medical, echoed the excitement regarding this collaboration: “We are excited to represent Tetrous in New Zealand and add their innovative EnFix implants to our portfolio. The high quality and uniqueness of Tetrous' solutions align perfectly with our commitment to New Zealand's healthcare professionals and patients.”

The EnFix® product line is designed to address a critical failure point in various orthopedic procedures, enhancing healing at the enthesis. The implants consist of 100% demineralized bone fiber (DBF), optimized for osteoinductivity and osteoconductivity. This results in superior biological performance with minimal disruption to standard surgical techniques, making it an ideal choice for practicing surgeons.

This new distribution agreement signifies not only growth for Tetrous in New Zealand but also highlights their ongoing efforts to deliver innovative solutions within the sports medicine domain. With these plans underway, Tetrous is dedicated to improving patient care through advanced medical technologies.

Founded in 2019, Tetrous, Inc. leverages state-of-the-art technologies for enthesis repair in sports medicine applications. The EnFix family of products originated from advancements initially created for spine surgery. To date, their core technology is credited with over 150,000 implanted devices in spine procedures alone, demonstrating a robust track record of success. Additionally, Tetrous holds significant intellectual property (IP) protection for the EnFix line, including multiple issued patents and exclusive licensing agreements for demineralized bone fiber technology from TheraCell, part of ISTO Biologics.

In conclusion, Tetrous, Inc.'s entry into the New Zealand market through this partnership with Alpha Medical and the inclusion of Dr. Craig Ball in their advisory board represents a strategic move towards global growth and innovation in the orthopedic field. With a commitment to improving outcomes and patient recovery, Tetrous is poised for substantial contributions to sports medicine and orthopedic recovery solutions.

For more details about Tetrous and their innovative products, visit Tetrous, Inc. or follow on LinkedIn.